Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
8.695 USD | +2.05% | -34.74% | -15.81% |
05-13 | Morgan Stanley Lowers Price Target on NeuroPace to $9.50 From $13, Keeps Equalweight Rating | MT |
05-08 | NeuroPace, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-15.81% | 245M | |
+11.80% | 225B | |
+10.48% | 186B | |
+12.75% | 135B | |
+25.39% | 107B | |
+0.76% | 63.56B | |
+5.62% | 51.32B | |
+12.12% | 51.04B | |
+8.44% | 43.3B | |
+4.47% | 36.99B |
- Stock Market
- Equities
- NPCE Stock
- News NeuroPace, Inc.
- Earnings Flash (NPCE) NEUROPACE Reports Q4 Revenue $18M, vs. Street Est of $17.7M